CompaniesPrexton Therapeutics

Prexton Therapeutics

defunct
About

Defunct Company

Areas of Focus

Categories

Terminally AcquiredBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (3)
View all

Total Trials

3

As Lead Sponsor

3

As Collaborator

0

Total Enrollment

221

By Phase

PHASE2: 2PHASE1: 1

By Status

COMPLETED: 2WITHDRAWN: 1
Clinical Trials Pipeline3 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2015
2016
2017
2018
2019
2020
2021
Today
NCT03162874
Hover over trial bars to see details

Recent Trials

NCT03331848Lead Sponsor
Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)
PHASE2Withdrawn
Started: Jan 15, 2018 · Completed: Feb 1, 2019
NCT03162874Lead Sponsor
Study to Evaluate the Efficacy, Safety and Tolerability of PXT002331 (Foliglurax) in Reducing Motor Complications of Levodopa Therapy in Parkinson Disease's Patients
PHASE2Completed
157 participants
Started: Jul 4, 2017 · Completed: Mar 2, 2020
NCT02639221Lead Sponsor
A Phase I, Double Blind, Placebo Controlled, First in Human, Single and Multiple Ascending Oral Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male and Female Subjects
PHASE1Completed
64 participants
Started: Jan 31, 2016 · Completed: Sep 30, 2016
Related Companies
Lundbeck
acquired